IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience Research Letter

  

Authors:	Gangat, N.; Ajufo, H.; Abdelmagid, M.; Karrar, O.; McCullough, K.; Badar, T.; Foran, J.; Palmer, J.; Alkhateeb, H.; Mangaonkar, A.; Kuykendall, A.; Rampal, R. K.; Tefferi, A.
Title:	IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience
Keywords:	adult; clinical article; aged; middle aged; gene mutation; hydroxyurea; myeloid metaplasia; drug safety; monotherapy; cytarabine; letter; low drug dose; multiple cycle treatment; gene frequency; relapse; dna methylation; febrile neutropenia; mitoxantrone; recurrent disease; allogeneic hematopoietic stem cell transplantation; pancytopenia; hyperbilirubinemia; karyotyping; granulocyte colony stimulating factor; cytogenetic analysis; azacitidine; myeloproliferative neoplasm; polycythemia vera; thrombocythemia; cladribine; isocitrate dehydrogenase 1; clinical outcome; idh1 gene; idh2 gene; high throughput sequencing; decitabine; isocitrate dehydrogenase 2; very elderly; human; male; female; fedratinib; differentiation syndrome; venetoclax; enasidenib; ivosidenib; blast phase myeloproliferative neoplasm
Journal Title:	British Journal of Haematology
Volume:	203
Issue:	3
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2023-11-01
Start Page:	e87
End Page:	e92
Language:	English
DOI:	10.1111/bjh.19027
PUBMED:	37537750
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166624070&doi=10.1111%2fbjh.19027&partnerID=40&md5=8611005785716a1a7367d5df9d171035
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/211540